Minimal residual disease in leukaemia patients
Top Cited Papers
- 1 July 2001
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 2 (7) , 409-417
- https://doi.org/10.1016/s1470-2045(00)00418-6
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)Leukemia, 2000
- Detection of minimal residual disease in acute leukemia by flow cytometryCytometry, 1999
- Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALLLeukemia, 1999
- Immunophenotypic and immunogenotypic characteristics of TCRγδ+ T cell acute lymphoblastic leukemiaLeukemia, 1999
- Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemiaLeukemia, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vβ antibodiesLeukemia, 1998
- Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.Journal of Clinical Pathology, 1996
- Disappearance of AML1 ‐MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long‐term remissionBritish Journal of Haematology, 1995
- Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of inductionThe Lancet, 1994